Pay in 4 interest-free payments of $5.84 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
This work was supported by the Wilmot Cancer Institute Predoctoral Fellowship (G.A.), Wilmot Cancer Institute Pilot Funding (I.S.H.), the American Association for Cancer Research and Breast Cancer Research Foundation (20-20-26-HARR) (I.S.H.), Breast Cancer Coalition of Rochester (I.S.H.), a Sir Henry Wellcome Postdoctoral Fellowship (M.E.K.), and a FNR-CORE grant C21/BM/15796788 (D.B.), and NIH grants R01CA269813 (I.S.H.), R37CA230042 (G.M.D), R24AA022057 (V.V.), R01AA028859 (Y.C.), AI150698 (J.M.), K01CA240533-01A1 (C.L.C.), and R01AR078000 (R.T.D.)
Complement Ther Med
This product is manufactured and sold strictly for laboratory research, in vitro signaling models, and controlled in vivo studies
It is available through compounding pharmacies for investigational and clinical off-label use, but it should only be sourced through a licensed, reputable compounding pharmacy under physician oversight
Source : This study investigates the in vitro metabolism of four growth hormone-releasing hormone (GHRH) synthetic analogs, including sermorelin, in fortified urine for anti-doping purposes
Bi J, Wang XB, Chen L, Hao S, An LJ, Jiang B, et al
US$ 26.35
US$ 28.77
US$ 24.69
US$ 27.55
